31 results about "Premenstrual syndrome (PMS)" patented technology

The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviate depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and / or reduced libido. The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

The invention provides a progesterone ethosome. Progesterone is encapsulated in an ethosome. The progesterone ethosome comprises the following components in percentage by weight: 0.1 to 1 percent of progesterone, 1 to 8 percent of lipid materials, 0 to 0.6 percent of cholesterol, 20 to 50 percent of short-chain alcohols, 0 to 3 percent of nonionic surfactant and the balance of water. The preparation method comprises the following steps of: mixing and dissolving the progesterone, the lipid materials, the cholesterol and the short-chain alcohols to prepare an alcohol phase; with stirring, adding the alcohol phase into a nonionic surfactant-containing aqueous phase to prepare primary emulsion under the condition of stirring; homogenizing the primary emulsion under a high pressure to obtain asuspension; stirring the ethosome suspension for 15 to 30 minutes to perform emulsification for the second time; and curing the suspension by cooling the suspension at 0 to 4 DEG C to obtain the progesterone ethosome. Because the high-pressure homogenization method is adopted to prepare the progesterone ethosome, the progesterone ethosome is low in stimulation to skin and high in transdermal delivery ability, and metal ion pollution which is easy to cause by the probe ultrasound method of the traditional homogenization method is avoided. Therefore, the progesterone ethosome is suitable for industrial production. The progesterone ethosome can be prepared into a transdermal drug delivery system, a mucosal drug delivery system, and topical dosage forms, such as a paster, a gel and the like. The progesterone ethosome is mainly applied to hormone replacement therapy, secondary amenorrhea, functional aplastic bleeding, premenstrual syndrome and the like clinically.

The present invention is directed to a screening mechanism for identifying members of the general population at increased risk for alcoholism and premenstrual syndrome. The screening mechanisms may be used to measure the expression of the α4β2δ GABAA receptors, in order to identify members of the general population as having an increased sensitivity to lower concentrations alcohol coupled with a decrease sensitivity to higher concentrations of alcohol, a scenario frequently found in patients suffering from alcoholism and premenstrual anxiety. Methods of screening for drugs which decrease expression of the α4β2δ subunit of GABAA are also provided.

A lighting control system includes: a biological information obtainer (10) which obtains biological information related to a biological body of a user; an environmental information obtainer (20) which obtains environmental information related to a surrounding environment of the user; a severity determiner (40) which determines a severity of premenstrual syndrome (PMS) based on the biological information obtained by the biological information obtainer (10) and the environmental information obtained by the environmental information obtainer (20); and a lighting controller (50) which controls a lighting device based on the severity determined by the severity determiner (40).

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and / or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selded from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reprodudive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The invention discloses an edible health borage oil microcapsule for women and a preparation method of the borage oil microcapsule. The capsule mainly comprises the following main raw materials: borage oil, corn syrup and sodium caseinate. The preparation method of the borage oil microcapsule comprises the following steps: homogenizing the raw materials under high pressure, spray drying the raw materials and preparing the raw materials into powder, sieving and packing to obtain borage oil microcapsule powder. The borage oil microcapsule prepared by the method is and is safe and non-toxic, and raw materials are easily available; the preparation method is simple in process, low in cost and suitable for large-scale production. The borage oil microcapsule can be widely used in solid beverage powder such as milk tea, milk powder and the like so as to provide a health food for women with the effects of relieving premenstrual syndrome and climacteric syndrome, improving skin elasticity and restoring the skin gloss.

The invention relates to nutritional food with effect of improving health of female in climacteric stage, which comprises (wt%) calcium carbonate 6.25-25.00, soybean protein isolate 6.25-12.50, spirulina 12.50-25.00, soybean isoflavones 1.25-3.12, Angelica sinensis extract 0.62-3.75, rhizoma polygonati extract 0.62-2.50, acanthopanax senticosus extract 5.00-11.25, schisandra chinensis fruit extract 1.25-3.75, vitamin C 0.75-1.25, vitamin E 0.25-0.62, ferric sodium ethylenediamine tetracetate 0.25-1.25, microcrystalline cellulose 64.81-9.61, and polyethylene glycol 0.20-0.40. The inventive food has the effects of improving premenstrual syndrome and female physiological function, retaining normal secretion of hormone, relieving climacteric symptoms, promoting metabolic function of human body and organs, relieving osteopenia, and delaying aging.

The invention discloses a traditional Chinese medicine composition for preventing and treating premenstrual syndromes and a preparation method of the traditional Chinese medicine composition, relatesto the technical field of traditional Chinese medicines and aims to solve the technical problems that a conventional medicine for treating premenstrual syndromes is not remarkable in treatment effect,and the like. The traditional Chinese medicine composition comprises the following active components in parts by mass: 20 parts of theanine, 10 parts of gelatine powder, 3-5 parts of polygonatum sibiricum powder, 9-11 parts of lycium barbarum powder, 0.8-1.2 parts of radix angelicae powder and 0.8-1.2 parts of lotus leaf powder. The preparation method comprises the following steps: mixing the theanine, the gelatine powder, the polygonatum sibiricum powder, the lycium barbarum powder, the radix angelicae powder and the lotus leaf powder; performing dry mixing on sucralose, microcrystalline cellulose, calcium carbonate and calcium lactate; uniformly spraying 70% ethanol, and stirring so as to obtain wet granules; performing drying treatment on the wet granules; performing finishing treatment; mixing with magnesium stearate; inspecting the granules, tableting, screening, coating with membranes, and discharging tablets. The traditional Chinese medicine composition is capable of effectively treating and relieving premenstrual syndromes and is low in cost, high in treatment rate and not liable in disease reoccurrence.

The invention provides a progesterone ethosome. Progesterone is encapsulated in an ethosome. The progesterone ethosome comprises the following components in percentage by weight: 0.1 to 1 percent of progesterone, 1 to 8 percent of lipid materials, 0 to 0.6 percent of cholesterol, 20 to 50 percent of short-chain alcohols, 0 to 3 percent of nonionic surfactant and the balance of water. The preparation method comprises the following steps of: mixing and dissolving the progesterone, the lipid materials, the cholesterol and the short-chain alcohols to prepare an alcohol phase; with stirring, adding the alcohol phase into a nonionic surfactant-containing aqueous phase to prepare primary emulsion under the condition of stirring; homogenizing the primary emulsion under a high pressure to obtain asuspension; stirring the ethosome suspension for 15 to 30 minutes to perform emulsification for the second time; and curing the suspension by cooling the suspension at 0 to 4 DEG C to obtain the progesterone ethosome. Because the high-pressure homogenization method is adopted to prepare the progesterone ethosome, the progesterone ethosome is low in stimulation to skin and high in transdermal delivery ability, and metal ion pollution which is easy to cause by the probe ultrasound method of the traditional homogenization method is avoided. Therefore, the progesterone ethosome is suitable for industrial production. The progesterone ethosome can be prepared into a transdermal drug delivery system, a mucosal drug delivery system, and topical dosage forms, such as a paster, a gel and the like. The progesterone ethosome is mainly applied to hormone replacement therapy, secondary amenorrhea, functional aplastic bleeding, premenstrual syndrome and the like clinically.